CALMARE® Pain Therapy Treatment
Project Number:
Marineo-01-07
Patent Numbers:
US patented
FDA 510(k) clearance for US sales
European Union Medical Device CE approved as an electronic-analgesic apparatus
Inventor:
The technology is from the research of Professor Giuseppe Marineo, a researcher and bioengineer, and the founder and manager of Delta Research & Development. Delta R&D, formed in May 1998, is a Medical Bioengineering Research Centre affiliated with Tor Vergata University of Rome in Italy.
Description:
The pain therapy technology is a non-invasive method for rapid treatment of high-intensity oncologic, neuropathic, and drug-resistant pain through a biophysical rather than a biochemical manner. The method incorporates electromedical equipment for electronic nerve stimulation, and uses the nerve fiber as a passive means to convey a message of normality to the central nervous system (CNS) by a procedure defined as scrambling or tricking of information, which then enables the CNS to modify the reflex adaptive responses - referred to as TEMPR - Transcutaneous Electrical Modulation Pain Reprocessor. It has been successfully used on over 3,000 patients in Europe.
Advantages:
The non-invasive MC-5A, using Scrambler Therapy® technology, is a multiprocessor apparatus able to simultaneously treat multiple pain areas in the individual. The patient experiences longer "no pain" periods after each successive treatment.
Applications:
The global pain management market is estimated to reach $60 billion by 2015. Potential market opportunities include hospitals, nursing homes and hospices, cancer treatment centers, and pain management centers.

For more information please contact:

Conrad F. Mir
President, CEO and Director
Calmare Therapeutics Incorporated
This email address is protected. Javascript must be enabled to view it.
Tel: 973.798.8882